Dr. Martin Gleave, MD, FRCSC, FACS
Chief Executive Officer, PC-TRiADD
Distinguished Professor and Head, Department of Urologic Sciences, UBC
Executive Director, Vancouver Prostate Centre
BC Leadership Chair in Prostate Cancer Research
Dr. Gleave is a clinician-scientist and urologic surgeon. His major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr. Gleave established a role for clusterin as a cancer-related cell survival protein involved in treatment resistance and developed an inhibitor, designated OGX-011, which improved efficacy of hormone- and chemo-therapies in prostate and other cancer models. He is the scientific founder of OncoGenex Pharmaceuticals Inc.
Dr. Larry Goldenberg, CM, OBC, MD, FRCSC, FACS, FCAHS, DABU
Professor, Department of Urologic Sciences, UBC
Stephen A. Jarislowski Chair in Urologic Sciences at VGH
Director of Development and Supportive Care, Vancouver Prostate Centre
Dr. Goldenberg is a urologic surgeon and clinical scientist with an international reputation for excellence in prostate cancer research and treatment. His current research involves the evaluation of the role of multiparametric MRI in prostate cancer, the potential use of focal therapy, patient education, daVinci robotic prostatectomy and novel treatments for benign prostatic hyperplasia. He has been recognized for his contributions to health care by being inducted into the Order of British Columbia and the Order of Canada.
Dr. Paul Rennie, PhD, FCAHS
Professor, Dept. of Urologic Sciences, UBC
Director, Laboratory Research, Vancouver Prostate Centre
Dr. Rennie is a PhD research scientist. His current research is aimed at determining how androgens regulate gene transcription and how to use this knowledge to prevent progression to androgen independence in prostate cancers. He is also studying prostate-specific elements of gene promoters and working to develop lenti and herpes virus-based vectors as a targeting vehicle for delivery and prostate-specific expression of genes that can control or kill prostate tumour cells.
Dr. Graeme Boniface, B. Pharm, PhD
Chief Operating Officer, Vancouver Prostate Centre
Chief Operating Officer, PC-TRiADD
Dr. Boniface joined the Prostate Centre as COO after more than 20 years in drug development in both the academic and private industry sectors. Most recently he was Senior Director of Clinical Research at QLT Inc. where he oversaw the clinical development of the company’s drug platform in Oncology, Urology, Dermatology, and Endocrinology indications. Trials conducted by his team have lead to successful regulatory marketing approvals by the US FDA, Canadian, and European agencies.
Mr. Brian Shankaruk, CGA
Chief Financial Officer, Vancouver Prostate Centre
Chief Financial Officer, PC-TRiADD
Brian Shankaruk has over 25 years experience in the financial field. For the last 20 years Brian has worked in the insurance and financial services industry, focusing on Canadian and US statutory government reporting. Brian studied accounting at UBC and received his Certified General Accountant designation in 1990. Much of Brian's recent work has involved systems design and implementation, especially as it relates to operations management and government regulations.